Application of direct renin inhibition to chronic kidney disease. - Wikidata - awgldk - TriplyDB

Application of direct renin inhibition to chronic kidney disease.

Application of direct renin inhibition to chronic kidney disease.

http://www.wikidata.org/entity/Q37758534

about

Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility Short- and long-term physiologic and pharmacologic control of blood pressure in pediatric patients.Proteases and protease inhibitors of urinary extracellular vesicles in diabetic nephropathy.Peripheral blood-derived endothelial progenitor cell therapy prevented deterioration of chronic kidney disease in rats.The role of direct renin inhibition in clinical practice: focus on combination therapy.Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor.Combination therapy of exendin-4 and allogenic adipose-derived mesenchymal stem cell preserved renal function in a chronic kidney disease and sepsis syndrome setting in rats.

P2860

Q27684098-14801CD5-BFAC-4FF8-A83D-617722A8D9FE Q35210549-54783D36-D98F-4DD7-AC2E-98BF05580FC2 Q35248154-F836F21B-43AB-426F-8099-F977FC536A86 Q35826445-BC9BF64B-08E1-4C57-A4C2-639FF209C84B Q37918526-27F1F9DF-324F-4637-B2F6-0BDBFEC1C906 Q41473977-B56FC204-BB45-47F4-85A0-0B8411078524 Q47138464-8CBDDC2E-6AE9-4F74-A358-2424D1955100

P2860

Application of direct renin inhibition to chronic kidney disease.

http://www.wikidata.org/entity/Q37758534

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Application of direct renin inhibition to chronic kidney disease.

@en

Application of direct renin inhibition to chronic kidney disease.

@nl

type

label

Application of direct renin inhibition to chronic kidney disease.

@en

Application of direct renin inhibition to chronic kidney disease.

@nl

prefLabel

Application of direct renin inhibition to chronic kidney disease.

@en

Application of direct renin inhibition to chronic kidney disease.

@nl

P1433

Q37758534-86C366C5-131B-4747-A47D-9E37F2B0B7C7

P1476

Q37758534-23081740-0CAA-4098-87AD-B9829D6046A4

P2093

Q37758534-22CDCD25-C9E8-4961-B253-20F3812A95E9

P2860

Q37758534-004895C0-0FD9-463A-B371-5878272F1841

Q37758534-15826906-27BC-432E-A1FD-F3E52C40A89F

Q37758534-16465263-6CC0-4C3A-9558-A8D0E2A8A64A

Q37758534-189550A4-21DC-43EB-A30F-9F31B6221380

Q37758534-1E8E09D2-6306-4561-BF61-3DAD3CACE514

Q37758534-2A5106AA-8266-4B05-9951-0B3C81C9C33A

Q37758534-2ADE71C0-8F2E-48FB-8C37-2C76D80812B2

Q37758534-2C08648A-B9C5-491E-9906-71999C7C6A67

Q37758534-303ABFCC-ADC1-47AA-819C-42F0BC2D2D30

Q37758534-33A4B523-2752-4D19-8EF4-CA8E6529BEEF

P304

Q37758534-89AD6B6B-23E9-4264-A863-E3684ABD8EED

P31

Q37758534-264D2A29-023E-4465-ABE6-5D4E70247F4B

Q37758534-E7D010F7-974E-43F9-BF67-08304A7F02CC

P356

Q37758534-F6A56AF2-8EDC-4152-A41E-D9636402F9CA

P433

Q37758534-4F823601-D959-49A8-9BD0-B93E5FC340AB

P478

Q37758534-64735921-24AB-427E-A237-0ED644F87A4D

P577

Q37758534-CCB38222-E534-4E50-A8FE-7B126DDA866D

P5875

Q37758534-0F3B7FBD-1D42-4C76-905F-92AF91984387

P698

Q37758534-444677B5-BF70-4F6D-AE16-D2A108453F18

P921

Q37758534-54C35761-4872-4D47-AD7A-DCF35B68C089

Q37758534-BC3C8CD3-47F7-477D-B43E-D6C14E2C1914

P932

Q37758534-073598DE-4179-490D-B5A5-B43340702100

P356

S10557-010-6232-1

P1433

Cardiovascular Drugs and Therapy

P1476

Application of direct renin inhibition to chronic kidney disease.

@en

P2093

Christian W Mende

http://www.w3.org/2001/XMLSchema#string

P2860

Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin

Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms

Supramaximal dose of candesartan in proteinuric renal disease

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

Aldosterone as a determinant of cardiovascular and renal dysfunction

Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification

P304

139-149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10557-010-6232-1

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44619190

http://www.w3.org/2001/XMLSchema#string

P698

20490905

http://www.w3.org/2001/XMLSchema#string

P921

chronic kidney disease

P932

2887501

http://www.w3.org/2001/XMLSchema#string